| Literature DB >> 34045179 |
A Vega1,2,3, T W Jimenez-Rodriguez2,4, R Barranco2,5, J Bartra2,6, M C Diéguez2,5, I Doña2,7,8, M Fernández-Rivas2,9, M Gandolfo-Cano2,10, G Gastaminza-Lasarte2,11, E González-Mancebo2,10, B de la Hoz Caballer2,12,13, L Sánchez-Morillas2,9, M J Torres2,7,8, M P Berges-Gimeno2,12, R Muñoz-Cano2,6.
Abstract
Rapid drug desensitization has enabled first-line therapies in patients with drug hypersensitivity reactions to chemotherapeutic drugs including monoclonal antibodies. Desensitization is a safe and highly effective procedure, not only for IgE-mediated reactions, but also for those mediated by non-IgE mechanisms. The likelihood of breakthrough reactions during desensitization is low, and most are mild; in fact, moderate-to-severe reactions are infrequent. In this document, 16 allergy departments belonging to the Spanish research network ARADyAL present a review of the available scientific evidence and provide general guidelines for the diagnosis and management of drug hypersensitivity reactions to chemotherapeutic drugs and monoclonal antibodies. Emphasis is placed on the desensitization procedure.Entities:
Keywords: Chemotherapy; Desensitization; Drug allergy; Drug challenge; Drug hypersensitivity; Monoclonal antibodies
Mesh：
Substances：
Year: 2021 PMID： 34045179 DOI： 10.18176/jiaci.0712
Source DB: PubMed Journal: J Investig Allergol Clin Immunol ISSN： 1018-9068 Impact factor: 4.333